# Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

> **NCT02783625** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 114 (actual)

## Conditions studied

- Lymphoma
- Relapsed/Refractory T-cell Lymphomas

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** Bortezomib
- **DRUG:** duvelisib

## Key facts

- **NCT ID:** NCT02783625
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-23
- **Primary completion:** 2026-04-21
- **Final completion:** 2026-04-21
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02783625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02783625, "Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02783625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*